Qmx Gold Corp (QMXGF) 0.0214 $QMXGF
QMX Gold Reports Revenue of $6.67 Million and Operational Cash Flow of $1.78 Million in Q2 2014
ACCESSWIRE - Tue Sep 09, 4:01PM CDT
Toronto, Ontario / ACCESSWIRE / September 9, 2014 / QMX GOLD CORPORATION (TSXV:QMX)("QMX" or the "Company"

produced 5,165 ounces of gold from its Lac Herbin mine in Val D'Or, Quebec in Q2 2014. The mine generated revenue of $6.67 million on the sale of 5,038 ounces of gold at an average realized price of $1,401 per ounce. All figures are reported in Canadian dollars, unless noted otherwise.
QMX Gold Sells Falco Shares
ACCESSWIRE - Fri Sep 05, 4:32PM CDT
Toronto, Ontario / ACCESSWIRE / September 5, 2014 / QMX GOLD CORPORATION (TSXV:QMX)("QMX" or the "Company"

announces that, further to its press release dated July 7, 2014, it has sold a portion of its block of common shares (the "Shares"

held in Falco Resources Ltd. ("Falco"

in three separate transactions for aggregate gross proceeds of $1,732,500. In addition, QMX intends to sell an additional 3,150,000 common shares of Falco that are subject to an escrow agreement at a price of $0.27 per share, subject to the policies of the TSX Venture Exchange.
Sulliden Mining Capital announces acquisition of common shares of Falco Resources
CNW Group - Fri Sep 05, 4:30PM CDT
Sulliden Mining Capital Inc. (TSX: SMC) ("Sulliden" or the "Company"

announces that by share purchase agreement with QMX Gold Corporation (QMX: TSXV), it has agreed to acquire 1,180,505 common shares (the "Purchased Shares"

of Falco Resources Ltd. ("Falco"

at $0.45 per share for an aggregate purchase price of $531,227.25, representing approximately 1.6% of the issued and outstanding common shares of Falco.
Osisko Gold Royalties Announces Acquisition of Common Shares of Falco Resources
Marketwire - Fri Aug 29, 8:26AM CDT
Osisko Gold Royalties Ltd (the "Company" or "Osisko"

(TSX: OR) is pleased to announce that by share purchase agreement (the "Share Purchase Agreement"

with QMX Gold Corporation (the "QMX Gold"

(TSX VENTURE: QMX) dated August 28, 2014, it has agreed to acquire 1,488,990 common shares (the "Purchased Shares"

of Falco Resources Ltd. ("Falco"

for an aggregate purchase price of $670,045.50, representing approximately 2.04% of the issued and outstanding common shares of Falco (the "Transaction"

.
QMX Gold Signs Agreement to Extend Convertible Debentures to October 1, 2014
ACCESSWIRE - Tue Aug 12, 4:01PM CDT
Toronto, ON / ACCESSWIRE / August 12, 2014 / QMX GOLD CORPORATION (TSXV:QMX)("QMX" or the "Company"

and its debentureholders have agreed to amend the convertible debenture dated April 28, 2010 to extend the maturity date of the convertible debentures to October 1st, 2014. The convertible debentures have an aggregate value of $4.2 million (plus interest) and were due to be repaid on April 28, 2014.
QMX Gold Agrees to Extend the Closing on the Sale of the Snow Lake Property
Marketwire - Mon Jul 07, 8:01PM CDT
QMX Gold Corporation (TSX VENTURE: QMX) ("QMX" or the "Company"

and Northern Sun Mining Corp. ("Northern Sun"

have agreed to an extension of the closing of the proposed acquisition by Northern Sun of the Snow Lake property, detailed in the press release dated October 2, 2013. The closing is now expected to occur on or before September 30, 2014.
QMX Reports Revenue of $30.62 Million and Operational Cash Flow of $5.45 Million for 2013
Marketwire - Tue Apr 01, 7:04AM CDT
QMX GOLD CORPORATION (TSX VENTURE: QMX) ("QMX" or the "Company"

sold 22,209 ounces of gold at an average price of $1,428 for revenue of $30.62 million in 2013. All figures are reported in Canadian dollars, unless noted otherwise.
QMX Gold Produces Over 22,000 Ounces of Gold in 2013 from Lac Herbin Mine
Marketwire - Tue Feb 25, 6:04AM CST
QMX GOLD CORPORATION (TSX VENTURE: QMX) ("QMX Gold" or the "Company"

produced approximately 7,260 ounces of gold from its Lac Herbin Mine in Val D'Or, Quebec in the fourth quarter of 2013. This brings total production for 2013 to over 22,200 ounces of gold, in line with Company guidance. Full financial details will be released in March 2014.
QMX to Begin Trading on TSX Venture Exchange on February 20, 2014
Marketwire - Tue Feb 18, 6:02AM CST
QMX GOLD CORPORATION (TSX: QMX) ("QMX Gold" or the "Company"

announces that its common shares (the "Shares"

have been approved for listing on the TSX Venture Exchange. The Shares will be delisted from the Toronto Stock Exchange at the close of business on Wednesday, February 19, 2014 and commence trading on the TSX Venture Exchange at the open of business on Thursday, February 20, 2014 under the ticker symbol QMX.
QMX Continues Trading on the TSX Until February 24, 2014
Marketwire - Mon Feb 10, 6:01AM CST
QMX GOLD CORPORATION (TSX: QMX) ("QMX Gold" or the "Company"

has received notice from the TSX that common shares of the Company will continue trading on the TSX until February 24, 2014 while the Company continues to pursue listing of its common shares on the TSX Venture Exchange as outlined in the press releases dated December 10th and 11th, 2013. While a listing on the TSX Venture Exchange is not guaranteed, this extension helps a smooth transition of the listing of the Company's common shares from the TSX without a disruption in trading.
Best's Rating Notification - Mercury County Mutual Insurance Company
Rating Division - AMBest - Fri Jan 31, 10:34AM CST
A.M. Best Company has made the following rating update:
QMX Gold Extends Loan Facility With Third Eye Capital
Marketwire - Tue Jan 28, 4:31PM CST
QMX GOLD CORPORATION (TSX: QMX) ("QMX Gold" or the "Company"

and Third Eye Capital Corporation ("TEC"

have signed an amending agreement that will further extend the term of the bridge loan facility provided by TEC until March 31, 2014 and be subject to the same terms and conditions outlined in the Company's press release dated October 9th, 2013.
Global Orphan Drug Pipeline Analysis
M2 - Fri Jan 17, 3:54AM CST
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry. With close to 65-70 Million people in the US & Europe having some kind of rare disease complaints, the increasing activities around the development of orphan drugs only imply that the appropriate treatments for unmet needs are increasing, thus increasing the profit margins in the future. As the Asian pharmaceutical markets are still in growth stage, the opportunities for orphan drugs in Asia are also immense and getting increasingly popular. It is expected that by 2020, the Asian orphan drugs market would witness steady growth.